{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-006382","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.829815+00:00","generated_at":"2026-06-25T21:47:11.942581+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zomedica Q1 revenue $3.8M, up 38% pro forma; net loss $3.9M","bullets":["Revenue $3.8M (74% gross margin) vs $14K in Q1 2021; up 38% over combined Zomedica+PulseVet $2.7M.","PulseVet revenue $3.7M (+36% vs standalone Q1 2021); small animal unit sales 30 (+500% YoY).","TRUFORMA product revenue $57K (+307% vs $14K); launched endogenous ACTH assay in April 2022.","Cash $192.3M at quarter end; net loss $3.9M ($0.004/share) vs $36.0M loss in Q1 2021.","SG&A $6.7M (+91% YoY) driven by share-based comp and sales force expansion; R&D $351K."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-006382","json":"https://secwatch.observer/filing/0001654954-22-006382.json","markdown":"https://secwatch.observer/filing/0001654954-22-006382.md","text":"https://secwatch.observer/filing/0001654954-22-006382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495422006382/0001654954-22-006382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495422006382/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:47:11.942581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}